Dong Fang Liu
Directeur Technique/Scientifique/R&D chez NUVATION BIO INC.
Fortune : 15 720 $ au 30/04/2024
Postes actifs de Dong Fang Liu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NUVATION BIO INC. | Directeur Technique/Scientifique/R&D | 18/07/2022 | - |
Historique de carrière de Dong Fang Liu
Anciens postes connus de Dong Fang Liu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| 3D MEDICINES INC. | Directeur Technique/Scientifique/R&D | 11/01/2019 | 01/03/2021 |
| CELGENE | Directeur/Membre du Conseil | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Formation de Dong Fang Liu
| Beijing Medical University | Undergraduate Degree |
| University of Toledo (Ohio) | Graduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
| Îles Cayman | 2 |
| Chine | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| 3D MEDICINES INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| NUVATION BIO INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bourse
- Insiders
- Dong Fang Liu
- Expérience